AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Up 78.6% in January

AngioDynamics, Inc. (NASDAQ:ANGO) was the recipient of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,470,000 shares, an increase of 78.6% from the January 15th total of 822,900 shares. Based on an average daily volume of 677,900 shares, the days-to-cover ratio is currently 2.2 days.

Analyst Ratings Changes

Separately, HC Wainwright boosted their price objective on shares of AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a report on Friday, January 10th.

Insider Activity at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the transaction, the senior vice president now owns 41,817 shares in the company, valued at approximately $514,767.27. The trade was a 8.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new position in AngioDynamics during the third quarter worth $103,000. CWM LLC boosted its holdings in AngioDynamics by 981.3% during the third quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock worth $76,000 after purchasing an additional 8,832 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in AngioDynamics by 7.2% during the third quarter. Assenagon Asset Management S.A. now owns 425,108 shares of the medical instruments supplier’s stock worth $3,307,000 after purchasing an additional 28,499 shares during the last quarter. Ballentine Partners LLC acquired a new position in AngioDynamics during the third quarter worth $141,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in AngioDynamics during the third quarter worth $86,000. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Stock Down 1.8 %

AngioDynamics stock opened at $10.34 on Friday. The stock has a market capitalization of $418.46 million, a PE ratio of -1.84 and a beta of 0.60. AngioDynamics has a twelve month low of $5.26 and a twelve month high of $13.50. The company has a 50 day moving average of $10.49 and a 200-day moving average of $8.32.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.07. The company had revenue of $72.90 million during the quarter, compared to analysts’ expectations of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business’s quarterly revenue was down .1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.05) earnings per share. Equities analysts anticipate that AngioDynamics will post -0.37 EPS for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.